TY - JOUR T1 - Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial JO - BMJ Open UR - http://dx.doi.org/10.1136/bmjopen-2023-083582 PY - 2024/02/05 AU - Brittain G AU - Petrie J AU - Duffy KEM AU - Glover R AU - Hullock K AU - Papaioannou D AU - Roldan E AU - Beecher C AU - Bursnall M AU - Ciccarelli O AU - Coles AJ et al ED - DO - DOI: 10.1136/bmjopen-2023-083582 PB - BMJ VL - 14 IS - 2 SP - e083582 EP - e083582 Y2 - 2025/03/17 ER -